Clinical Trial Update: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]

View source ↗

Summary

A Phase II trial evaluating cetuximab with or without OSI-906 in head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• OSI-906 (OSI-906)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: WITHDRAWN